Preclinical News and Research

RSS

Advances in stem cell research

Scientists at The University of Texas Health Science Center at Houston are on the forefront of stem cell research, developing novel therapies designed to generate heart cells, repair traumatic lung injuries, grow new bone and stanch the spread of cancer cells.

8 Mar 2009

Stem cell breakthrough gives new hope to sufferers of myopathy and muscular dystrophy

An experimental procedure that dramatically strengthens stem cells' ability to regenerate damaged tissue could offer new hope to sufferers of muscle-wasting diseases such as myopathy and muscular dystrophy, according to researchers from the University of New South Wales (UNSW).

5 Mar 2009

Diabetes linked to cognitive deterioration

Blindness, renal failure, stroke and heart disease are potential complications of type 2 diabetes, which currently afflicts more than 15 million Americans.

5 Mar 2009

Tuberculosis breakthrough could lead to stronger vaccine

A breakthrough strategy to improve the effectiveness of the only tuberculosis vaccine approved for humans provided superior protection against the deadly disease in a pre-clinical test, report scientists at The University of Texas Health Science Center at Houston in Nature Medicine 's Advance Online Publication March 1.

3 Mar 2009

FDA provides positive review of InNexus' lead preclinical drug candidate

InNexus Biotechnology Inc. has announced the United States Food & Drug Administration (FDA) has completed its comprehensive review of the development plans for InNexus' lead preclinical candidate, DXL625 (CD20) for the prospective treatment of Non-Hodgkin's Lymphoma (NHL) and/or Chronic Lymphocytic Leukemia (CLL).

3 Mar 2009

FDA clears Cellectar's IND application for lead drug candidate

Cellectar, Inc. has announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for its (131)I-CLR1404 drug candidate for testing in patients with advanced solid malignancies.

3 Mar 2009

Angiogenesis inhibitors, study points to limitations, solutions

A new generation of cancer drugs designed to starve tumors of their blood supply - called "angiogenesis inhibitors"-succeeds at first, but then promotes more invasive cancer growth-sometimes with a higher incidence of metastases, according to a new study in animals.

2 Mar 2009

Two compounds show great promise for cerebral palsy

Two compounds developed by Northwestern University chemists have been shown to be effective in pre-clinical trials in protecting against cerebral palsy, a condition caused by neurodegeneration that affects body movement and muscle coordination.

25 Feb 2009

Mindset BioPharmaceuticals receives notice of allowance for European patent related to insulin sensitizers in dementia and memory loss

Mindset BioPharmaceuticals (USA) Inc ("MINDSET") a company privately held by MPM Capital and other shareholders announced today that it has received a Notice of Allowance in Europe related to patent applications describing the use of insulin sensitizer drugs for the prevention and treatment of memory loss.

24 Feb 2009

Ambrx and Merck Serono expand collaboration through multiple sclerosis drug

Ambrx Inc, and Merck Serono have announced a global strategic collaboration to develop and commercialize Ambrx's ARX424 preclinical product candidate for the treatment of multiple sclerosis.

24 Feb 2009

Scientists identify lab-made proteins that neutralize a broad range of influenza A viruses

Scientists have identified a small family of lab-made proteins that neutralize a broad range of influenza A viruses, including the H5N1 avian virus, the 1918 pandemic influenza virus and seasonal H1N1 flu viruses.

23 Feb 2009

Researchers examine role of high cholesterol in prostate cancer

Current research suggests that lowering cholesterol may block the growth of prostate tumors.

23 Feb 2009

Statins can stimulate cardiac muscle cell regeneration, improve heart function

Statins, used widely to treat elevated cholesterol, have been shown to prevent progression of coronary narrowing and to have other beneficial effects on the heart, such as reducing inflammation, that are independent of cholesterol.

23 Feb 2009

Bavarian Nordic updates on breast cancer vaccine studies

Bavarian Nordic today provided updated data from its clinical studies with its breast cancer vaccine, MVA-BN(R)-HER2, in development as therapy of metastatic breast cancer patients whose tumours over-express HER2.

23 Feb 2009

Scientists identify lab-made proteins that neutralize multiple strains of seasonal and pandemic flu

22 Feb 2009

Neuralstem's ALS trial on hold

Neuralstem, Inc. has announced its spinal cord stem cell trial to treat Amyotrophic Lateral Sclerosis (ALS) is on clinical hold and that the Federal Drug Administration (FDA) has provided the Company with specific comments, questions and recommendations for modifications to its protocol.

22 Feb 2009